Research Topics
| Brian I RiniSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinomaBrian I Rini
Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
Cancer 106:566-75. 2006..Based on potential additive or synergistic antitumor effects, interferon-alpha (IFNalpha) and celecoxib, an oral COX-2 inhibitor, were given to metastatic RCC patients in a Phase II trial...
Surgical resection of renal cell carcinoma after targeted therapyAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA
J Urol 182:881-6. 2009..The integration of targeted therapy and surgery requires careful consideration due to the potential for increased perioperative morbidity...- AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 studyBrian Rini
The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Cancer 118:6152-61. 2012.... - The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgeryBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave Desk R35, Cleveland, Ohio 44195, USA
J Urol 187:1548-54. 2012..We investigated the effect of sunitinib on locally advanced primary renal carcinoma tumors and the ability to facilitate subsequent surgery... 
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsSamuel E DePrimo
Translational Medicine, Pfizer Global Research and Development, La Jolla, CA, USA
J Transl Med 5:32. 2007....- Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastasesBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
Clin Genitourin Cancer 5:232-4. 2006..Herein, we report 2 cases of patients with cytokine-refractory metastatic RCC who received sunitinib and achieved sufficient decrease in tumor burden to permit subsequent surgical resection, resulting in long-term CR... - Current status and future directions of molecular markers in renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Curr Opin Urol 16:332-6. 2006..To describe the existing data regarding the prognostic and/or predictive value of molecular markers in metastatic renal cell carcinoma... - Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206Brian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
J Clin Oncol 26:5422-8. 2008..Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospective, randomized phase III trial of bevacizumab plus IFN versus IFN monotherapy was conducted... - Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene statusBrian I Rini
Department of Medicine, The University of California San Francisco, San Francisco, California, USA
BJU Int 98:756-62. 2006..To describe the relationship among patient characteristics, Von Hippel-Lindau (VHL) gene status and clinical outcome in metastatic renal cell carcinoma (RCC) in patients receiving vascular endothelial growth factor (VEGF)-targeted therapy... - Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II studyBrian I Rini
Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
Biol Blood Marrow Transplant 12:778-85. 2006..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC... - Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Cancer 107:67-74. 2006..A clinical trial was conducted to determine the prostate-specific antigen (PSA) and immunomodulatory effects of this combination immunotherapy... - Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
Cancer 115:2306-12. 2009..Future directions include investigation of combination and sequenced therapy, elucidation of mechanisms of response and resistance, and exploration of the effect of these agents in other disease settings... - Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Urol Oncol 26:543-9. 2008..Several relevant clinical aspects have also emerged with use of these agents such as defining resistance, measurement of response, and combination therapy... - Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
J Clin Oncol 26:3743-8. 2008..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response... - Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 113:1309-14. 2008..Cytopenia and macrocytosis have been described in patients treated with these agents... - Molecularly targeted therapy in renal cell carcinoma: where do we go from here?Brian I Rini
Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
Expert Rev Anticancer Ther 6:1753-60. 2006..These issues are discussed in light of current data and strategies for further drug development are presented... - Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinibBrian I Rini
Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
J Natl Cancer Inst 99:81-3. 2007..Thyroid function test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted... - Temsirolimus, an inhibitor of mammalian target of rapamycinBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Clin Cancer Res 14:1286-90. 2008 - Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directionsBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
Clin Cancer Res 13:1098-106. 2007..This article also reviews future development strategies, including combination regimens and drug sequencing, trial design considerations, and patient selection opportunities... - SunitinibBrian I Rini
Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue Desk R35, Cleveland, Ohio 44195, USA
Expert Opin Pharmacother 8:2359-69. 2007..Despite these initial results, several questions remain to optimize the utility of this agent... - What is standard initial systemic therapy in metastatic renal cell carcinoma?Brian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, OH 44195, USA
Clin Genitourin Cancer 5:256-63. 2007..As new standard therapies for metastatic RCC emerge, clinical trial conduct remains a priority to further optimize patient outcome... - Metastatic renal cell carcinoma: many treatment options, one patientBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
J Clin Oncol 27:3225-34. 2009..There are thus potentially many different treatment approaches to each metastatic RCC patient. This review discusses how to integrate the available data regarding targeted therapy in metastatic RCC into personalized cancer care... - VEGF-targeted therapy in renal cell carcinoma: active drugs and active choicesBrian I Rini
Cleveland Clinic Foundation, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
Curr Oncol Rep 8:85-9. 2006..The biology, clinical results, and future considerations regarding VEGF-targeted agents in RCC are presented in this article... - New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistanceBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urologic and Kidney Institute, Cleveland, Ohio 44195, USA
Clin Cancer Res 16:1348-54. 2010..Several treatment strategies have emerged that are in the early phases of clinical testing. Further clinical and translational research is needed to validate initial hypotheses and translate observations into novel treatment strategies... - Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factorBrian I Rini
University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
J Urol 175:2087-91. 2006..We describe the clinical and immunological characteristics of patients with biochemically relapsed prostate cancer who achieved long-term disease control with GM-CSF (Leukine)... - Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave Desk R35, Cleveland, OH 44195, USA
J Clin Oncol 28:2137-43. 2010..Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC. A prospective, randomized, phase III trial of bevacizumab plus IFN-alpha versus IFN-alpha monotherapy was conducted... - Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
Cancer 117:758-67. 2011.... - Resistance to targeted therapy in renal-cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urologic and Kidney Institute, 9500 Euclid Avenue Desk R35, Cleveland, OH 44195, USA
Lancet Oncol 10:992-1000. 2009..Clinical data support activity of several agents in resistant patient populations, with large-scale clinical trials ongoing to more thoroughly test several postulations regarding the optimum clinical approach... - Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
J Natl Cancer Inst 103:763-73. 2011..We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse events in patients with metastatic renal cell carcinoma... - Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumorsBrian I Rini
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Clin Cancer Res 17:3841-9. 2011..To evaluate if diastolic blood pressure (dBP) ≥90 mm Hg during axitinib treatment is a marker of efficacy... - Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini
Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
Lancet 378:1931-9. 2011.... - Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?Brian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland, Ohio 44195, USA
Oncology (Williston Park) 22:388-96; discussion 396, 402-3, 476 passim. 2008..Novel agents targeting the VEGF or alternative pathways have also emerged and are beginning to undergo clinical testing... - A phase I study of sunitinib plus bevacizumab in advanced solid tumorsBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Clin Cancer Res 15:6277-83. 2009..The safety and maximum tolerated dose of sunitinib plus bevacizumab was assessed in this phase I trial... - SorafenibBrian I Rini
Department of Solid Tumour Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Expert Opin Pharmacother 7:453-61. 2006..Sorafenib is well tolerated, with common toxicities including rash, diarrhoea, hand-foot skin reaction, fatigue and hypertension, when administered as the standard dose of 400 mg b.i.d... - SU11248 and AG013736: current data and future trials in renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA
Clin Genitourin Cancer 4:175-80. 2005..Substantial clinical activity has been reported for these agents in metastatic RCC trials, leading to additional investigations in a variety of settings... - Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future developmentBrian I Rini
Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
BJU Int 96:286-90. 2005 - Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
J Clin Oncol 27:4462-8. 2009.... - Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyJuan Barbastefano
Department of Medicine, Cleveland Clinic, Cleveland, OH, USA
BJU Int 106:1266-9. 2010.... - Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyToni K Choueiri
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
Cancer 110:543-50. 2007..The identification of patients who are more likely to benefit from these agents is warranted... - Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinomaAnil A Thomas
Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Urol 181:518-23; discussion 523. 2009..We assessed the activity of neoadjuvant sunitinib on primary renal tumors in patients with advanced renal cell carcinoma as well as the feasibility and safety of subsequent surgical resection... - Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyAli Reza Golshayan
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
J Clin Oncol 27:235-41. 2009..The utility of vascular endothelial growth factor (VEGF)-targeted therapy in patients with this disease is unknown... - Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapyIla Tamaskar
Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
J Urol 179:81-6; discussion 86. 2008..Currently, several agents with a putative antiangiogenic mechanism exist and they are often being used in sequence with little to no data regarding activity in a second line or later setting... - The role of targeted therapy in metastatic renal cell carcinomaJaya Unnithan
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
ScientificWorldJournal 7:800-7. 2007..This article briefly describes the biological pathways involved in the development of RCC and the results of clinical trials using targeted therapy in metastatic RCC... - A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancerAmy M Lin
UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
Clin Genitourin Cancer 5:323-8. 2007..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models... - Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumabJorge A Garcia
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 116:5383-90. 2010..Despite common use, the safety and activity of sorafenib in bevacizumab- or sunitinib-refractory mRCC have not been prospectively investigated... - The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinibNaveen S Basappa
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 117:1183-9. 2011..However, to the authors' knowledge, the impact of TB characteristics on clinical outcome has not been studied in patients with mRCC who were treated with vascular endothelial growth factor-targeted therapy... - Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small
UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
J Clin Oncol 22:1025-33. 2004..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy... - Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:16-24. 2006..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC... - Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
JAMA 295:2516-24. 2006..Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown activity in an initial study of cytokine-refractory metastatic RCC patients... - A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapyAmy M Lin
University of California/San Francisco, San Francisco, CA 94115, USA
BJU Int 98:763-9. 2006.... - Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostainingAnita Schwandt
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
J Clin Immunol 31:690-8. 2011..A phase II trial of celecoxib and IFN-α in a targeted population of metastatic renal cell carcinoma patients with maximal COX-2 expression was conducted... - A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small
UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
Clin Cancer Res 13:1810-5. 2007.... - Recent progress in the management of advanced renal cell carcinomaJorge A Garcia
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, OH, USA
CA Cancer J Clin 57:112-25. 2007..This generation of novel molecular targeted therapies continues to show great promise. The purpose of this review is to summarize the current management and to discuss potential future directions in the management of metastatic RCC... - Targeted therapy in renal cell carcinomaBhanu K Vakkalanka
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Curr Opin Urol 18:481-7. 2008..A better understanding of renal cell carcinoma biology has led to a new era of targeted therapy in the management of metastatic renal cell carcinoma... - Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinomaSaby George
Division of Hematology and Oncology, Department of Medicine, The University of Texas Health Science Center, San Antonio, TX 78229, USA
Clin Genitourin Cancer 6:79-85. 2008..In vitro experiments demonstrated that suramin, at noncytotoxic doses, enhanced the activity of chemotherapy including 5-fluorouracil (5-FU) in xenograft models... - Phase II study of lenalidomide in patients with metastatic renal cell carcinomaToni K Choueiri
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
Cancer 107:2609-16. 2006..A Phase II, open-label study of LEN in patients with metastatic renal cell carcinoma (RCC) was conducted to determine its safety and clinical activity... - Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapyAndrew Dennis Smith
Imaging Institute, Cleveland Clinic, Cleveland, OH 44195, USA
AJR Am J Roentgenol 194:1470-8. 2010..Target lesions were assessed on routine contrast-enhanced CT (CECT) images obtained during the portal venous phase using new response criteria... - Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSFLawrence Fong
Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
Cancer Res 69:609-15. 2009.... - Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaBrian I Rini
University of California at San Francisco, San Francisco, California 94115, USA
Clin Cancer Res 10:2584-6. 2004..A Phase III trial is now being conducted randomizing untreated, metastatic clear cell RCC patients to IFN-alpha alone or IFN-alpha plus Avastin... - Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinomaJorge A Garcia
Division of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center and Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA
BJU Int 109:63-9. 2012..c.) interleukin-2 (IL-2), interferon-α2b (IFN-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF)... - Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Clin Cancer Res 13:741s-746s. 2007..VEGF-Trap is also a VEGF binding molecule with ongoing investigation in RCC... - Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinomaDaniel Y C Heng
Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Clin Genitourin Cancer 5:446-51. 2007..Additionally, nCRs can be seen despite nonpulmonary metastatic sites and previous VEGF-targeted therapy... - Sunitinib rechallenge in metastatic renal cell carcinoma patientsIvan N Zama
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
Cancer 116:5400-6. 2010.... - Renal cell carcinomaBrian I Rini
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
Curr Opin Oncol 20:300-6. 2008..This study is intended to update prognostic and therapeutic decision-making data and provide perspective on advances in understanding the molecular biology of this disease... - Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinomaBrian I Rini
UCSF Comprehensive Cancer Center, The University of California San Francisco, 1600 Divisadero, Rm A717, San Francisco, CA 94115, USA
Cancer 101:90-5. 2004..Given the historically low objective response rate in RCC, time to disease progression (TTP) as an alternative endpoint was employed to evaluate the antitumor activity of UCN-01 in RCC... - Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reportsPhilip E Shaheen
Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
Clin Genitourin Cancer 5:78-81. 2006..We report 2 cases highlighting that efficacy of these agents is possible after failure of the other agent. Further prospective study is needed... - The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight
Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA
Prostate 69:142-8. 2009..One vaccination strategy that is being pursued in the clinic utilizes peptide-pulsed peripheral blood mononuclear cells (PBMC) + IL-12... - Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trialJorge A Garcia
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH, USA
BJU Int 107:562-70. 2011..To determine the clinical and immunomodulatory effects of this combination, a prospective, phase II trial of bevacizumab plus low-dose IL-2 was conducted... - Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patientsJennifer S Ko
Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
Clin Cancer Res 15:2148-57. 2009..Several factors pivotal to the accumulation of MDSC are targeted by the tyrosine kinase inhibitor, sunitinib. The effect of sunitinib on MDSC-mediated immunosuppression in RCC patients has been investigated... - A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinomaBrian I Rini
Department of Hematology Oncology, The University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
Cancer 103:553-8. 2005..Fixed dose rate gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical effect. To determine the toxicity of this combination therapy in metastatic RCC, a Phase I trial was conducted... - Practice and progress in kidney cancer: methodology for novel drug developmentBrian I Rini
Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
J Urol 171:2115-21. 2004..Furthermore, we describe new paradigms for the evaluation of novel agents to optimize the yield of clinical research in RCC... - Renal cell carcinomaBrian I Rini
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
Curr Opin Oncol 18:289-96. 2006.... - Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapiesSaby George
Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Clin Genitourin Cancer 5:S40-4. 2006..This review will examine the existing data in this setting, describe ongoing clinical investigations, and discuss challenges unique to this patient population... - VEGF-targeted therapy in metastatic renal cell carcinomaBrian I Rini
1600 Divisadero, Room A717, San Francisco, California 94115, USA
Oncologist 10:191-7. 2005..To review the biology of renal cell carcinoma (RCC) and the clinical results of vascular endothelial growth factor (VEGF) blockade in metastatic RCC... - Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinomaBrian I Rini
University of California San Francisco Comprehensive Cancer Center, CA, USA
J Clin Oncol 23:1028-43. 2005..To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC... - Technology evaluation: APC-8015, DendreonBrian I Rini
UCSF Comprehensive Cancer Center, San Francisco, CA 94115, USA
Curr Opin Mol Ther 4:76-9. 2002..In April 2001, Dendreon was awarded US-06210662 covering the therapeutic composition of APC-8015 [406383]... - The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapyBrian I Rini
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center and Section of Urological Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Urol 177:1978-84. 2007..Accomplishing this in the current era of targeted molecular therapies presents unique challenges and opportunities... - Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunitiesDonna E Hansel
Department of Anatomic Pathology, Glickman Urological and Kidney Institute and Taussig Cancer Institute, The Cleveland Clinic, 9500 Euclid Avenue, Desk L25, Cleveland, OH 44195, USA
Expert Rev Anticancer Ther 8:895-905. 2008.... - Prostate cancer updateBrian I Rini
University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
Curr Opin Oncol 14:286-91. 2002..This article reviews the major advances in prostate cancer published between November 1, 2000, and October 31, 2001... - Immunotherapy for metastatic renal cell carcinomaDavid F McDermott
DF/HCC Renal Cancer Program, Beth Israel Deaconess Medical Center, Boston, MA, USA
BJU Int 99:1282-8. 2007 - Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinomaToni K Choueiri
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 26:127-31. 2008..The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated... - Molecularly targeted therapy in renal cell carcinomaW Kimryn Rathmell
Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7295, Chapel Hill, NC 27599 7295, USA
Expert Rev Anticancer Ther 5:1031-40. 2005..However, investigation is needed to optimally utilize these agents at the appropriate stage of disease and in the best combinations for maximal clinical benefit... - The potential for prostate cancer immunotherapyBrian I Rini
University of California San Francisco UCSF Comprehensive Cancer Center, USA
Crit Rev Oncol Hematol 46:S117-25. 2003..Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen... - Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini
University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
J Clin Oncol 20:2017-24. 2002..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression... - Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyOlivier Rixe
Pitie Salpetriere Hospital, University of Paris, Paris, France
Lancet Oncol 8:975-84. 2007..We aimed to assess the activity and safety of axitinib in patients with metastatic renal-cell cancer who had failed on previous cytokine-based treatment... - Quantifying hypertension in patients with cancer treated with sorafenibBrian I Rini
Lancet Oncol 9:86-7. 2008 - The current role of angiogenesis inhibitors in the treatment of renal cell carcinomaToni K Choueiri
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Semin Oncol 33:596-606. 2006..This review will describe the current clinical data with VEGF-targeted approaches in RCC and plans for future development... - Axitinib for renal cell carcinomaGuru Sonpavde
Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA
Expert Opin Investig Drugs 17:741-8. 2008..Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor... - Renal cell carcinomaW Kimryn Rathmell
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599 7295, USA
Curr Opin Oncol 17:261-7. 2005..Given historically limited advances in this disease, a more thorough understanding and testing of rationally targeted agents is needed... - Clinical trials in patients with biochemically relapsed prostate cancerAmy M Lin
UCSF Comprehensive Cancer Center, University of California/San Francisco, San Francisco, CA 94115, USA
BJU Int 97:905-10. 2006..Finally there are two papers from Australia describing the use of positron emission tomography in renal cancer and in prostate cancer... - Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancerGarth Beinart
Department of Hematology/Oncology, M. D. Anderson Cancer Center, USA
Clin Prostate Cancer 4:55-60. 2005..Further manipulations of host immunity may be required to achieve a significant antitumor effect... - von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaToni K Choueiri
Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
J Urol 180:860-5; discussion 865-6. 2008..The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear... - Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinomaG Kesava Reddy
CIG Media Group, LP, Dallas, TX, USA
Clin Genitourin Cancer 5:110-3. 2006..However, optimal dose, treatment schedule, selection of patients, and appropriate combination strategies with other novel agents need to be defined for mTOR-targeted therapies in the treatment of advanced-stage RCC...
Research Grants
- Therapeutic Modulation of COX-2-induced Immunosuppression in Metastatic RCCBrian Rini; Fiscal Year: 2007..This project will have broad implications for the immunoregulation of cancer and how expression and modulation of COX-2 expression influences the immune response to cancer. ..